Second-line treatment for advanced colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new treatment for people with advanced colorectal cancer that has spread or come back after initial chemotherapy. It is for those who have already received standard first-line therapy and are now looking for a second treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with colorectal cancer that has spread or returned after initial treatment.
- You received a specific first-line therapy including fluoropyrimidine, oxaliplatin, and a targeted drug (bevacizumab or cetuximab).
- You have at least one tumor that can be measured on scans.
- Your major organs (bone marrow, kidneys, liver) are working well enough on blood tests.
- You have not had irinotecan as part of your first treatment.
- You do not have certain gene changes that make immunotherapy the better option (dMMR/MSI-H).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two oral cancer drugs, trifluridine/tipiracil and fufuquitinib, as a third-line treatment for people with advanced colorectal cancer. It may be an option if prior treatments have stopped working.
This trial tests a new schedule of two drugs—bevacizumab and trifluridine/tipiracil—given every two weeks instead of more often. The goal is to reduce severe low white blood cell counts (neutropenia) while still treating advanced colorectal cancer that has not responded to several previous treatments.
This trial tests a combination of three drugs (irinotecan, TAS-102, and bevacizumab) for people with metastatic colorectal cancer that has already been treated with oxaliplatin-based chemotherapy. The goal is to see if this three-drug combination works better as a second treatment option.
This study tests a real-world treatment with a combination drug called Trifluridine/Tipiracil for people with metastatic colorectal cancer. It aims to see how well it works and how safe it is in everyday medical practice.
This trial tests a chemotherapy drug (trifluridine/tipiracil) in people with metastatic colorectal or gastroesophageal cancer who have a DPD deficiency. DPD deficiency means your body may have trouble breaking down certain chemotherapy drugs, which can lead to serious side effects. This study aims to see if this drug is safe and effective for you.
This Phase 2 trial compares two treatment combinations as a first treatment for metastatic (spread) colon or rectal cancer. It looks to see whether one combo works better or is safer than the other.
Hear when a new Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.